Tagraxofusp-erzs (Elzonris) — Clinical FAQs

Q: Is Tagraxofusp-erzs safe during pregnancy?

Tagraxofusp-erzs pregnancy safety: Can cause fetal harm based on its mechanism of action. Women of reproductive potential should use effective contraception during treatment and for at least 1 week after the final dose. No adequate data in pregnant women. Breastfeeding not recommended during treatment and for 1 week after the final dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Question 1

What is Tagraxofusp-erzs FDA-approved to treat?

Accepted Answer

Tagraxofusp-erzs is FDA-approved for the following oncology indications: 1. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients aged 2 years and older — first approved therapy for this indication (December 2018; pivotal single-arm trial supporting accelerated approval).

Question 2

How does Tagraxofusp-erzs work (mechanism of action)?

Accepted Answer

Tagraxofusp is a first-in-class CD123-targeted cytotoxin consisting of recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin (DT) payload (catalytic and translocation domains). CD123, the IL-3 receptor alpha subunit, is expressed at high levels on blastic plasmacytoid dendritic cell neoplasm (BPDCN) cells and other hematologic malignancies. Upon binding of the IL-3 moiety to CD123 on the tumor cell surface, the fusion protein is internalized via receptor-mediated endocytosis. Within the endosome, the diphtheria toxin translocation domain facilitates transfer of the catalytic domain to the cytosol, where it ADP-ribosylates elongation factor-2 (EF-2), irreversibly halting protein synthesis and resulting in apoptotic cell death. This targeted delivery mechanism concentrates the cytotoxic payload specifically within CD123-expressing malignant cells.

Question 3

How is Tagraxofusp-erzs administered?

Accepted Answer

Tagraxofusp-erzs is administered Intravenous (IV). Recommended dose is 12 mcg/kg IV over 15 minutes once daily on days 1–5 of a 21-day cycle.

Question 4

What are the most common side effects of Tagraxofusp-erzs?

Accepted Answer

The most commonly reported side effects of Tagraxofusp-erzs (≥10% incidence) include: Capillary leak syndrome (any grade ~55% in clinical trials), Nausea, Fatigue, Peripheral edema, Pyrexia (infusion-related fever) and others (12 total). Consult your oncologist for complete prescribing information.

Question 5

Does Tagraxofusp-erzs have a black box warning?

Accepted Answer

Yes. Tagraxofusp-erzs carries FDA black box warning(s) regarding: 1. Capillary Leak Syndrome (CLS): Fatal capillary leak syndrome reported; assess serum albumin level before the initiation of each treatment cycle and on day 4 of each cycle; do not administer if albumin is <3.5 g/dL; monitor for signs and symptoms of CLS (hypotension, edema, weight gain, pulmonary edema, hemoconcentration) during and after infusion; may be rapidly fatal — interrupt infusion and manage aggressively with IV fluids, vasopressors, and corticosteroids as needed

Question 6

Is Tagraxofusp-erzs safe during pregnancy?

Accepted Answer

Tagraxofusp-erzs pregnancy safety: Can cause fetal harm based on its mechanism of action. Women of reproductive potential should use effective contraception during treatment and for at least 1 week after the final dose. No adequate data in pregnant women. Breastfeeding not recommended during treatment and for 1 week after the final dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

tagraxofusp-erzs — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms